This article is for informational and educational purposes only and does not constitute medical advice. Cagrilintide is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Novo Nordisk A/S. This research review is compiled from publicly available peer-reviewed literature for educational purposes only.
Cagrilintide (development designation AM833) is a long-acting synthetic analogue of human amylin (islet amyloid polypeptide, IAPP), engineered by Novo Nordisk to enable once-weekly subcutaneous dosing through fatty acid conjugation for albumin binding. It acts as an agonist at amylin receptors — heteromeric complexes of the calcitonin receptor with receptor activity-modifying proteins — and is proposed to suppress appetite through central satiety circuits, delay gastric emptying, and reduce postprandial glucagon secretion through mechanisms partially distinct from those of GLP-1 receptor agonists. Among the more extensively studied long-acting amylin analogues currently in clinical development, cagrilintide has been evaluated in Phase 1 pharmacokinetic studies, a Phase 2 dose-finding monotherapy trial, and Phase 3 trials as a combination therapy (CagriSema) with semaglutide 2.4 mg. Published Phase 2 data report body weight reductions of approximately 10.8% at the highest tested dose as monotherapy at 26 weeks. Phase 3 REDEFINE programme data for the cagrilintide–semaglutide combination have been reported as of the review date. Cagrilintide is not FDA-approved.
1. Background
1.1 Human Amylin (IAPP) — Endogenous Biology
Amylin, also designated islet amyloid polypeptide (IAPP), is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. It was first isolated and characterized in the late 1980s from amyloid deposits in type 2 diabetic pancreata and subsequently identified as a normal beta-cell secretory product [1]. Physiologically, amylin contributes to postprandial glucose control through three primary mechanisms: suppression of postprandial glucagon secretion, delay of gastric emptying to moderate the rate of nutrient absorption, and activation of central satiety circuits — particularly in the area postrema and nucleus tractus solitarius — to reduce food intake and promote fullness [2].
Native human amylin has two significant pharmacological liabilities that limit its therapeutic utility. First, it has a very short plasma half-life of approximately two to three minutes, owing to rapid proteolytic clearance. Second, and more critically, the human IAPP sequence is highly amyloidogenic: under physiological conditions it self-assembles into fibrillar structures that are cytotoxic to beta cells and form the pancreatic amyloid deposits characteristic of type 2 diabetes. Both liabilities must be addressed in analogues designed for therapeutic use.
1.2 Pramlintide as a First-Generation Amylin Analogue
Pramlintide (brand name Symlin) was the first approved amylin receptor agonist, receiving FDA approval in 2005 as an adjunct to insulin therapy for type 1 and type 2 diabetes. It is derived from the amylin sequence of the rat and European hamster, which differ from human amylin at three critical positions (25, 28, 29) with proline substitutions that prevent amyloid fibril formation while maintaining receptor activity. Pramlintide demonstrated reductions in HbA1c, postprandial glucose excursions, and modest weight loss in clinical trials, providing proof of concept for therapeutic amylin receptor agonism. However, pramlintide retains a short half-life of approximately 48 minutes and requires two to three subcutaneous injections per day, limiting its practical uptake.
1.3 Rationale for Long-Acting Amylin Analogues and Combination with GLP-1 Agonists
The commercial success of long-acting GLP-1 receptor agonists, and the observation that amylin and GLP-1 act through partially non-overlapping neural and peripheral circuits to reduce food intake, created the rationale for developing once-weekly amylin analogues. Amylin receptors and GLP-1 receptors are co-expressed in some hypothalamic and brainstem nuclei, but the downstream intracellular pathways differ: GLP-1 receptors signal primarily through Gs and cyclic AMP, while amylin receptors signal through both Gs and Gq pathways depending on the receptor subtype. Preclinical combination studies reported additive or greater-than-additive reductions in body weight when amylin and GLP-1 agonists were co-administered, supporting the clinical investigation of a fixed-dose combination [2].
Cagrilintide was developed by Novo Nordisk using the fatty acid conjugation strategy previously applied to semaglutide: attachment of a long-chain fatty acid via a mini-PEG-based linker at a lysine residue, enabling tight but reversible binding to serum albumin and a plasma half-life consistent with once-weekly dosing.
2. Molecular Structure and Design
Cagrilintide is a synthetic 37-amino acid peptide derived from the human amylin sequence, with multiple amino acid substitutions to prevent amyloidogenesis, and a C18 fatty diacid chain attached via a mini-PEG linker at a lysine residue. The precise sequence and substitution map are described in Novo Nordisk patent filings; the general engineering strategy is analogous to that used for semaglutide in the GLP-1 class. The molecular weight of cagrilintide is approximately 4,413 Da.
| Property | Human Amylin (IAPP) | Pramlintide | Cagrilintide |
|---|---|---|---|
| Length | 37 aa | 37 aa | 37 aa (+ fatty acid chain) |
| MW | ~3,906 Da | ~3,949 Da | ~4,413 Da |
| Amyloid prevention | None (aggregation-prone) | 3 Pro substitutions (positions 25, 28, 29) | Multiple substitutions |
| Half-life extension | None (~2–3 min) | None (~48 min; TID dosing) | C18 fatty diacid via mini-PEG linker at Lys residue (~7 days; QW dosing) |
| Dosing interval | Not applicable | 2–3× daily (with each meal) | Once weekly |
| Regulatory status | Not applicable | FDA-approved (Symlin, 2005) | Phase 3; not approved |
Schematic log-scale representation; bar lengths are not proportional to absolute half-life values. Native amylin and pramlintide half-life values are literature estimates; cagrilintide half-life is approximate based on Phase 1 pharmacokinetic data consistent with once-weekly dosing. Individual pharmacokinetic values vary by dose, population, and study conditions.
3. Mechanism of Action
The mechanisms below reflect the established pharmacology of amylin receptor agonism, supported by convergent evidence from in vitro receptor pharmacology, pramlintide clinical data, and preclinical combination studies. Cagrilintide-specific mechanistic data are consistent with the class but more limited in depth relative to the broader amylin literature.
4. Key Research Findings
4.1 Amylin Receptor Pharmacology — Foundation from Pramlintide
The mechanistic foundation for cagrilintide as an amylin receptor agonist rests on an established body of pharmacological evidence accumulated over three decades. Hay et al. (2015) reviewed the amylin receptor pharmacology literature in detail, characterizing the CTR–RAMP receptor complexes, tissue expression patterns, signal transduction pathways, and structure–activity relationships for amylin analogues [2]. Pramlintide’s FDA approval in 2005, based on multiple randomized controlled trials demonstrating reductions in HbA1c and body weight in patients with type 1 and type 2 diabetes, established proof of concept for the amylin receptor as a therapeutically relevant target. Cagrilintide’s clinical development builds on this mechanistic framework: the compound is designed to activate the same receptor complexes with improved pharmacokinetics.
4.2 Phase 2 Monotherapy — Weight Management
A multicentre, randomised, double-blind, placebo-controlled and active-controlled dose-finding Phase 2 trial evaluated once-weekly cagrilintide in adults with overweight or obesity (without type 2 diabetes) across multiple dose levels [4]. At 26 weeks, the highest-dose cagrilintide group achieved approximately 10.8% reduction in body weight from baseline compared with approximately 3% in the placebo group. Dose-dependent weight loss was observed across the tested dose range, with tolerability consistent with the amylin class — primarily nausea and vomiting of mild-to-moderate severity, predominantly early in treatment. This Phase 2 monotherapy study established the dose range and initial efficacy signal that informed the combination programme.
4.3 CagriSema Phase 1b — Combination with Semaglutide
Enebo et al. (2021) published a randomised, placebo-controlled, double-blind Phase 1b multiple-dose trial evaluating cagrilintide co-administered with semaglutide 2.4 mg in adults with overweight or obesity [3]. The primary objectives were pharmacokinetics, safety, and tolerability; secondary outcomes included body weight change. The study demonstrated that the pharmacokinetics of neither compound were materially altered by co-administration, supporting the feasibility of a fixed-dose combination. Weight loss observed in the combination arm exceeded that seen with either agent alone in the study population, providing the initial human evidence for additive or greater-than-additive weight loss with CagriSema that underpinned progression to Phase 3. Tolerability was consistent with the GLP-1 and amylin class profiles, with gastrointestinal adverse events being most frequent.
4.4 REDEFINE Phase 3 Programme
The REDEFINE clinical programme, sponsored by Novo Nordisk, enrolled participants across multiple Phase 3 randomised controlled trials to evaluate CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, once weekly) versus its individual components and placebo. Top-line results from REDEFINE 1 — which enrolled participants with obesity without type 2 diabetes — have been reported as of the review date, with the CagriSema combination demonstrating body weight reductions reported as approximately 22–23% from baseline at 68 weeks, exceeding the weight loss achieved by either semaglutide or cagrilintide alone in the trial [5]. Peer-reviewed publication of the full dataset, including responder analyses, subgroup data, and complete safety profiles, should be consulted for detailed interpretation.
Schematic representation of the cagrilintide clinical development programme. Timing is approximate. PK = pharmacokinetics; PD = pharmacodynamics. Review the primary publications and ClinicalTrials.gov listings for precise study timelines and current status.
5. Evidence Status
| Claim / Effect | Supporting Evidence | Evidence Level |
|---|---|---|
| Amylin receptor agonism (mechanism) | Established pharmacology from pramlintide clinical data and amylin receptor literature; cagrilintide receptor binding confirmed in vitro | Strong |
| Albumin binding enabling once-weekly dosing | Phase 1 PK data consistent with once-weekly dosing; mechanism analogous to semaglutide | Strong |
| Weight loss as monotherapy (Phase 2) | Randomised, double-blind, placebo-controlled Phase 2 trial; ~10.8% BW reduction at highest dose, 26 weeks | Moderate |
| Additive weight loss with semaglutide (Phase 1b/3) | Phase 1b RCT and REDEFINE Phase 3 top-line data reporting ~22–23% BW reduction at 68 weeks | Moderate–Strong |
| Gastric emptying delay and glucagon suppression | Established for pramlintide; cagrilintide pharmacodynamic data consistent with class effects | Moderate |
| Long-term cardiovascular outcomes | Not established; CV outcome trial data not published as of the review date | Limited |
| Efficacy or safety beyond 68 weeks | Published data confined to trial durations reported; long-term extension data not available as of review date | Limited |
What We Still Don’t Know
- Durability of weight loss: Published Phase 2 and Phase 3 trial data extend to 26–68 weeks. Whether the degree of weight loss is maintained, diminishes, or requires continuous dosing beyond that period has not been characterised in published peer-reviewed long-term extension studies.
- Relative contribution in the CagriSema combination: Phase 3 REDEFINE data compare CagriSema to each component and placebo, but the degree to which complementary neural and peripheral mechanisms versus simple additive receptor coverage accounts for the enhanced weight loss is not fully resolved from clinical data alone.
- Cardiovascular outcomes: GLP-1 receptor agonists have established CV outcome data; analogous long-term cardiovascular trial data for cagrilintide or CagriSema have not been published as of the review date.
- Effects in distinct subpopulations: REDEFINE 1 enrolled patients with obesity without type 2 diabetes. Efficacy and safety in patients with type 2 diabetes, heart failure, or kidney disease may differ; separate trial programmes address some of these populations but data may not be fully published as of the review date.
- Amyloid implications of chronic amylin receptor agonism: Native human amylin is amyloidogenic in the pancreas. Whether chronic exposure to a long-acting amylin analogue at supraphysiological levels has any implications for islet amyloid deposition, beta-cell function, or other off-target tissue amyloid has not been characterised in published long-term preclinical or clinical studies.
6. Limitations of Current Research
References
- Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM. “Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic cats.” Proceedings of the National Academy of Sciences USA. 1987;84(23):8628–8632.
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. “Amylin: pharmacology, physiology, and clinical potential.” Pharmacological Reviews. 2015;67(3):564–600. doi:10.1124/pr.114.009621
- Enebo JP, Berthelsen KK, Lund MT, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2·4 mg for obesity: a randomised, placebo-controlled, double-blind, multiple-dose phase 1b trial.” Lancet. 2021;397(10286):1736–1748.
- Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in adults with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” Lancet. 2021;398(10317):2160–2172.
- Novo Nordisk A/S. REDEFINE 1 (NCT05567796): Phase 3 randomised controlled trial of once-weekly CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) versus components and placebo for weight management in adults with obesity. Top-line results reported 2025. Peer-reviewed publication details to be confirmed; see ClinicalTrials.gov NCT05567796 and Novo Nordisk press communications for current status.